Drugs / BAR502
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06705998 | Dec 2024 → May 2026 overdue | metabolic dysfunction-associated steatohepatitis | BAR Pharmaceuticals s.r.l. | Recruiting | No outcome recorded |
| Phase 1 | NCT05203367 | Nov 2022 → Mar 2023 | NAFLD1 | BAR Pharmaceuticals s.r.l. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAR502 | “Drug: BAR502” NCT05203367 ↗ |
| Route | Oral | “Each subject will receive an oral single-dose of BAR 502.” NCT05203367 ↗ |